All In Biotech

Drug Trial Radar · NCT06168799

Ilofotase Alfa for Prevention of Renal Damage After Cardiac Surgery

Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ilofotase Alfa in Patients at Risk for Renal Damage Following Open Heart Surgery

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 271 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

271

Actual

Start

Dec 19, 2023

Primary completion

Oct 5, 2025

Study completion Dec 3, 2025

Sponsor

Lead sponsor
AM-PharmaIndustry
Sponsor type
Industry
Collaborators
FGK Clinical Research GmbH
First posted
Dec 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this clinical trial is to evaluate the efficacy and safety of two intravenous administrations of ilofotase alfa in patients at risk for renal damage following open heart surgery.

Conditions

  • Open Heart Surgery

Interventions

  • Ilofotase alfaDrug

    After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)

  • PlaceboDrug

    After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serum Creatinine Level RatioTime frame: From Baseline (Day -1/1) to Day 5

Locations

13 sites in 5 countries. Site status is shown where the registry gives one.

  • Ziekenhuis Oost Limburg

    Genk, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Algemeen Ziekenhuis Delta

    Roeselare, Belgium

  • Universität Duisburg-Essen, Klinik für Thorax- und Kardiovaskuläre Chirurgie

    Essen, Germany

  • Deutsches Herzzentrum Muenchen Des Freistaates Bayern Klinik An Der Technischen Universitaet Muenchen

    Munich, Germany

  • Westfaelische Wilhelms-Universitaet Muenster

    Münster, Germany

  • Universitätsklinikum für Anästhesiologie und Intensivmedizin, Universitätsklinikum Tübingen

    Tübingen, Germany

  • Academisch Medisch Centrum Amsterdam

    Amsterdam, Netherlands

  • Stichting Radboud University Medical Center

    Nijmegen, Netherlands

  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

    Rotterdam, Netherlands

  • Universitätsspital Bern Universitätsklinik für Herzchirurgie

    Bern, Switzerland

  • Centre hospitalier universitaire vaudois (CHUV)

    Lausanne, Switzerland

  • Guy's and St Thomas' NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.